Pharmaceutical compounds for use in the therapy of Clostridium difficile infection
AssigneeETH Zurich
InventorsBastien Castagner, Jean-Christophe Leroux, Mattias Ivarsson, Gisbert Schneider, Anna Pratsinis
Life of this patent
Estimating the term…
Abstract
The invention relates to a compound described by a general formula (1), wherein each X independently can be OPO32−, OPSO22− or OSO3−; R1 comprises a solubility function such as a polyethylene glycol moiety and each X independently can be OPO32−, OPSO22−, − or OSO3−; and Z is an alkyl chain comprising 1 to 3 carbon and/or hetero atoms. The invention further relates to polysulfate derivatives or mixed polyphosphate/sulphate derivatives of six-membered cyclic polyols for use in the therapy of infection by Clostridium difficile.
Claims3
A method for treating a C. difficile infection, comprising administering to a subject a composition comprising a compound described by general formula (16a) or (16b):
- wherein
- a) X2 is OSO3−, and X1, X3, X4, X5 and X6 are each independently selected from OPO32−, OPSO22− or OSO3−;
- b) X1, X3 and X5 are OPO32− and X2, X4 and X6 are OSO3−
- c) X1, X3 and X5 are OSO3− and X2, X4 and X6 are OPO32−
- d) X4, X5 and X6 are OSO3− and X1, X2 and X3 are OPO32−,
- e) X4, X5 and X6 are OPO32− and X1, X2 and X3 are OSO3− or
- f) X2 and X5 are OPO32− and X1, X3, X4, and X6 are OSO3−,
- g) X2 and X5 are OSO3− and X1, X3, X4, and X6 are OPO32−,
- h) X2 and X3 are OPO32− and X1, X4, X5, and X6 are OSO3−, or
- i) X2 and X3 are OSO3− and X1, X4, X5, and X6 are OPO32−.
Dependencies are inferred from the claim text.